Methods of treating ileus
The present invention relates to a method of treating ileus in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient.
1. A method of treating ileus in a patient, the method comprising:
identifying a patient suffering from ileus; and
administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 10,000 ppm, wherein the patient inhales the gaseous composition.
2. The method of claim 1 , wherein the ileus is ileus of the small intestine.
3. The method of claim 1 , wherein the ileus is ileus of the colon.
4. The method of claim 1 , wherein the ileus is ileus of the stomach.
5. The method of claim 1 , wherein the ileus is post-surgical ileus.
6. The method of claim 1 , wherein the ileus is post-partum ileus.
7. A method of treating ileus in a patient, the method comprising:
identifying a patient suffering from or at risk for ileus caused by an abdominal surgery selected from the group consisting of: surgery of the urogenital system; surgery of the digestive system; surgery of the lymphatic system; surgery of the respiratory system; surgery of the diaphragm; surgery to treat cancer; endometrial surgery; and orthopedic surgery; and
administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 10,000 ppm, wherein the patient inhales the gaseous composition.
8. The method of claim 7 , wherein the ileus is ileus of the small intestine.
9. The method of claim 7 , wherein the ileus is ileus of the colon.
10. A method of treating ileus in a patient, the method comprising:
identifying a patient suffering from or at risk for ileus not caused by surgery; and
administering to the patient a therapeutically effective amount of a gaseous composition comprising carbon monoxide at a concentration of about 10 ppm to about 10,000 ppm, wherein the patient inhales the gaseous composition.
11. A method of treating ileus in a patient, comprising:
(a) providing a vessel containing a pressurized gas comprising carbon monoxide gas;
(b) identifying a patient suffering from ileus;
(c) releasing the pressurized gas from the vessel, to form an atmosphere comprising carbon monoxide gas at a concentration of about 10 ppm to about 10,000 ppm; and
(d) exposing the patient to the atmosphere, wherein the amount of carbon monoxide in the atmosphere is a therapeutically effective amount sufficient to treat ileus in the patient and wherein the patient inhales the atmosphere.
12. The method of claim 1 , wherein the composition comprises carbon monoxide gas at a concentration of at least 50 ppm.
13. The method of claim 1 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of at least 100 ppm.
14. The method of claim 1 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of at least 250 ppm.
15. The method of claim 1 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of at least 500 ppm.
16. The method of claim 1 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of about 200 ppm to about 500 ppm.
17. The method of claim 1 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of about 150 ppm to about 600 ppm.
18. The method of claim 1 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of about 100 ppm to about 800 ppm.
19. The method of claim 1 , wherein the pharmaceutical composition contains carbon monoxide gas at a concentration of about 10 ppm to about 1000 ppm.
20. The method of claim 1 , wherein the pharmaceutical composition is administered to the patient through a ventilator.
21. The method of claim 7 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of at least 50 ppm.
22. The method of claim 7 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of at least 100 ppm.
23. The method of claim 7 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of at least 250 ppm.
24. The method of claim 7 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of at least 500 ppm.
25. The method of claim 7 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of about 200 ppm to about 500 ppm.
26. The method of claim 7 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of about 150 ppm to about 600 ppm.
27. The method of claim 7 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of about 100 ppm to about 800 ppm.
28. The method of claim 7 , wherein the pharmaceutical composition contains carbon monoxide gas at a concentration of about 10 ppm to about 1000 ppm.
29. The method of claim 7 , wherein the pharmaceutical composition is administered to the patient through a ventilator.
30. The method of claim 10 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of at least 50 ppm.
31. The method of claim 10 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of at least 100 ppm.
32. The method of claim 10 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of at least 250 ppm.
33. The method of claim 10 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of at least 500 ppm.
34. The method of claim 10 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of about 200 ppm to about 500 ppm.
35. The method of claim 10 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of about 150 ppm to about 600 ppm.
36. The method of claim 10 , wherein the pharmaceutical composition comprises carbon monoxide gas at a concentration of about 100 ppm to about 800 ppm.
37. The method of claim 10 , wherein the pharmaceutical composition contains carbon monoxide gas at a concentration of about 10 ppm to about 1000 ppm.
38. The method of claim 10 , wherein the pharmaceutical composition is administered to the patient through a ventilator.
39. The method of claim 11 , wherein the atmosphere comprises carbon monoxide at a concentration of at least 50 ppm.
40. The method of claim 11 , wherein the atmosphere comprises carbon monoxide at a concentration of at least 100 ppm.
41. The method of claim 11 , wherein the atmosphere comprises carbon monoxide at a concentration of at least 250 ppm.
42. The method of claim 11 , wherein the atmosphere comprises carbon monoxide at a concentration of at least 500 ppm.
43. The method of claim 11 , wherein the atmosphere comprises carbon monoxide gas at a concentration of about 200 ppm to about 500 ppm.
44. The method of claim 11 , wherein the atmosphere comprises carbon monoxide gas at a concentration of about 150 ppm to about 600 ppm.
45. The method of claim 11 , wherein the atmosphere comprises carbon monoxide gas at a concentration of about 100 ppm to about 800 ppm.
46. The method of claim 11 , wherein the atmosphere contains carbon monoxide at a concentration of about 10 ppm to about 1000 ppm.
47. The method of claim 11 , wherein the patient is exposed to the atmosphere via a ventilator.
48. The method of claim 1 , wherein the composition is in gas form and is administered to the patient via an artificial lung.
49. The method of claim 7 , wherein the composition is in gas form and is administered to the patient via an artificial lung.
50. The method of claim 10 , wherein the composition is in gas form and is administered to the patient via an artificial lung.
51. The method of claim 1 , wherein the ileus is associated with surgery, parturition, intestinal ischemia, retroperitoneal hematoma, intraabdominal sepsis, intraperitoneal inflammation, fracture of the spine, ureteric colic, thoracic lesions, basal pneumonia, rib fracture, or myocardial infarction.
52. The method of claim 10 , wherein the ileus is associated with parturition, intestinal ischemia, retroperitoneal hematoma, intraabdominal sepsis, intraperitoneal inflammation, fracture of the spine, ureteric colic, thoracic lesions, basal pneumonia, rib fracture, or myocardial infarction.
53. The method of claim 11 , wherein the ileus is associated with surgery, parturition, intestinal ischemia, retroperitoneal hematoma, intraabdominal sepsis, intraperitoneal inflammation, fracture of the spine, ureteric colic, thoracic lesions, basal pneumonia, rib fracture, or myocardial infarction.